Gilead Sciences Inc. (NASDAQ: GILD) Holds Steady as HIV and Oncology Portfolio Drives Income

Gilead Sciences Inc. (NASDAQ: GILD) Holds Steady as HIV and Oncology Portfolio Drives Income

Gilead Sciences Inc. (NASDAQ: GILD) was trading in a stable range on Friday, May 22, reflecting the stock’s defensive characteristics as a cash-generative biopharmaceutical company. Gilead has maintained a consistent position as one of the most reliable income-oriented holdings among NASDAQ-listed healthcare names, supported by its dominant position in HIV treatment. The company’s HIV portfolio, anchored by Biktarvy and Descovy, continues to gen…